Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma-Reference-Cited by-同舟云学术

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

Published:2010-03-08 Issue:1 Volume:100 Page:95-103
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Phuphanich Surasak,Supko Jeffrey G.,Carson Kathryn A.,Grossman Stuart A.,Burt Nabors L.,Mikkelsen Tom,Lesser Glenn,Rosenfeld Steve,Desideri Serena,Olson Jeffrey J.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Clinical Neurology,Neurology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11060-010-0143-7.pdf

Reference59 articles.

1. Adams J, Palombella VJ, Elliott PJ (2000) Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 18:109–121

2. King RW, Deshaies RJ, Peters JM, Kirschner MW (1996) How proteolysis drives the cell cycle. Science 274:1652–1659

3. Sherr CJ (1996) Cancer cell cycles. Science 274:1672–1677

4. Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T (1995) The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2:493–506

5. Tariman JD (2007) Current therapies for multiple myeloma. J Infus Nurs 30:113–118 quiz 121

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteasome Inhibitors against Glioblastoma—Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine;Current Oncology;2023-11-02

2. Photodynamic therapy for glioblastoma: A light at the end of the tunnel;Journal of Photochemistry and Photobiology;2023-02

3. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas;Frontiers in Immunology;2023-01-16

4. Graphene Oxide Nanoscale Platform Enhances the Anti‐Cancer Properties of Bortezomib in Glioblastoma Models;Advanced Healthcare Materials;2022-11-11

5. Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review;Journal of Neuro-Oncology;2022-08-06